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Abstract 
Objective: ANCA-associated vasculitis (AAV) is a rare multisystem disease. Modern 
therapeutic protocols have turned AAV from an acute frequently fatal disease into a 
chronic disease requiring long-term immunosuppression. Patients must often 
manage substantial burdens related to chronic illness and treatment-related side 
effects, requiring help from informal carers. This study aimed to explore the 
experience of patients and of informal carers of patients with AAV about the impact 
of managing a rare rheumatic condition.   
Methods: A qualitative approach using semi-structured interviews was used. 
Interviews were conducted with a purposeful sample of 18 pairs of patients with AAV 
and their informal carers. The interviews were used to explore the participants’ 
experience and effects of caring. The interviews were recorded and transcribed as 
verbatim text and analysed using the framework technique.
Results: 18 patients (seven female) [disease: ten granulomatosis with polyangiitis 
(GPA); four microscopic polyangiitis (MPA); four eosinophilic granulomatosis with 
polyangiitis (EGPA), age range 34-78, disease duration 1- 20 years. Caregiver and 
patient perspectives were shared. The emerging themes were the physical and 
psychological impact of the disease, the need for constant vigilance and fear of the 
future. 
Conclusion: Both patients and carers faced a range of challenges in managing a 
rare condition, from the seriousness of the illness, dealing with the emotional toll and 
knowing what to expect. This study offers insight into the experiences of patients and 
informal carers, and health care professionals should address individuals’ fears and 
expectations for recovery.   
Key words: ANCA-associated vasculitis, carers, challenges of a rare condition
Key messages
Carers play a key role in the management of patients with ANCA-associated 
vasculitis
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Carers carry a heavy burden of responsibility when caring for someone with ANCA-
associated vasculitis
Carers require support in their own right from health care professionals
Introduction
The ANCA-associated vasculitides (AAV) Granulomatosis with Polyangiitis 
(Wegener’s) (GPA), Eosinophilic Granulomatosis with Polyangiitis (Churg Strauss) 
(EGPA) and Microscopic Polyangiitis (MPA) are a group of rare, potentially life-
threatening conditions which if untreated can be fatal. Many organs can be affected 
such as the kidney, heart, lung, upper and lower airways and the nervous system. 
Modern immunosuppressive therapy, has changed the outlook for patients with AAV 
from being very poor with a high mortality to a chronic disease associated with a 
need for long-term treatment [1]. Despite improvements in survival there are 
significant side-effects of therapy such as increased risk of infection, hypertension, 
osteoporosis, diabetes associated with steroids, haematological and skin 
malignancies [2-7].  
The diagnosis of AAV has a physical, psychosocial and financial impact on patients’ 
lives [8-12]. The physical impact can cause a range of problems from hearing loss, 
blindness, shortness of breath, saddle nose deformity and nerve damage [3,13]. 
Disease-related complications such as stroke, myocardial infarction, kidney failure, 
cancer, blindness, stomach ulcer and seizures have been reported in 10% patients 
[14,16]. At five years the long-term side effects of corticosteroids are substantial: 
41% had hypertension, 38% osteoporosis, 28% diabetes mellitus and 25% had 
developed cataracts [3]. Fatigue is a major cause of impaired physical health and 
appears to be unresponsive to treatment [17-18]. Patients must often manage 
substantial burdens related to chronic illness and treatment-related side effects 
[3,8,10]. It is clear that the impact of a diagnosis of AAV is significant and patients 
need help and support to manage their disease. 
Informal carers are people who actively participate in the care of a patient on a 
practical and/or emotional basis,usually partners or family members. To date there is 
no knowledge about the role played by informal carers in the treatment and lives of 
patients with AAV and we need a better understanding of their role. 
The aim of this study was to explore the experience of patients and informal carers 
of patients with AAV about the impact of managing a rare rheumatic condition.  
Methods
Design 
A qualitative approach using semi-structured interviews was used because it enables 
the researcher to seek the views and opinions of individuals and gain an 
understanding and insight of their social world [19]. Semi-structured, one-to-one 
interviews allow the researcher to explore topics in-depth, discovering rich 
experiential data from participants about their experiences. It allows the researcher 
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to follow up interesting responses and adapt questions, not possible with self-
administered questionnaires [20]. An interview guide was prepared with a list of 
questions to facilitate this (supplementary material, available at Rheumatology 
Advances in Practice online) which was informed by the existing literature, patients 
and three health care professionals (one nurse, one consultant and one qualitative 
researcher) to agree the topics for discussion. This was piloted with three patients 
and three carers. 
Participants  
A purposeful sample of 18 pairs of patients with AAV and their informal carers were 
recruited in East Anglia (Table 1, 2). Patient and carer pairs were enrolled from two 
vasculitis specialist centres,with the consultant or vasculitis specialist nurse 
approaching potential participants, providing an information sheet and consent 
forms. If both patient and carer agreed to participate, they posted the consent form to 
the researchers, who contacted them directly and arranged the interview. Consent 
was obtained separately from patient and carer,with the patient asked to consent to 
their carer sharing personal information about them. 
Patients and carers were interviewed separately in order to obtain their independent 
views on the role of the caring. As these issues are often not discussed with each  
other. Interviews took place either in the hospital or the participant's home, or at a 
convenient location. Interviews lasted from 45 minutes to an hour. Ethical approval 
for the study was provided by the Norfolk Research Ethics Committee (ref 
16/EM/0190). 721     
Inclusion and Exclusion Criteria
Participants (both carers and patients) aged > 18 years with an adequate command 
of English. Patients with a confirmed diagnosis of AAV, classified using the EMA 
approach [21]. All had to be capable of giving informed consent. Informed consent 
was obtained. Patients and carers with severe medical conditions were not recruited.
Data analysis
The interviews were recorded on a digital recorder and transcribed as verbatim text. 
The transcriptions were read and analysed by two authors (J.M, K.G) using the 
framework technique [22], a five-step process which involves; Familiarization with 
the data; Identification of a thematic framework; Indexing; Charting; Mapping and 
interpretation.
This technique is a systematic and comprehensive method for researchers to 
analyse and make sense of data by mapping emergent themes or concepts that 
explain those data. Data were coded into developing descriptive categories, these 
were recorded onto charts, then analysed for patterns and mapped into key themes. 
This framework was then applied to the other transcripts and the themes were 
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further developed. The framework headings and subheadings identified were 
member-checked: i) a summary of headings identified was sent to interviewees; ii) 
they were invited to discuss their views on their clarity and authenticity in a telephone 
conversation with the facilitator to ensure the interpretation of the data was an 
accurate representation and understanding of participants’ views. Participants 
agreed with the themes and subheadings, no new categories emerged and no 
existing ones were amalgamated.
Results 
18 patients (seven female) [disease: ten GPA; four MPA; four EGPA, age range 34-
78, disease duration 1- 20 years]. Details are provided in Tables 1 and 2. Caregiver 
and patient perspectives were shared. The emerging themes were the physical and 
psychological impact of the disease, the need for constant vigilance and fear of the 
future (Figure 1). 
Physical and psychological impact of the disease
This theme describes the physical and emotional impact of the disease particularly 
during the acute phase of the illness. Patients reported extreme tiredness and 
weakness, being unable to walk and needing help with dressing and bathing. P3 
‘Yes, I fall asleep anywhere. And the fatigue - people don't believe you're fatigued, 
they just think you're lazy’. P3 ‘It's worse for her than it is for me, because I'm ill. 
She's getting all this and she ain't ill, bless her. She's missing out on so much. It's 
hard. There's no support for her whatsoever. She's had to dress me some days.. P9  
‘When I was really ill, he was actually doing everything’. 
Carers told of the physical help they provided and the psychological and emotional 
toll of caring for someone with a serious rare illness. C5 ‘When he came home - 
finally - it was the most frightening time, because he was wasted away. He'd lost so 
much weight, like a skeleton. And just walking to make a cup of tea was too much. It 
took months of work to bring back his strength’. C10 ‘Am I selfish?  I get a little bit 
cross when she gets tired but I also get cross with her when she brings it on - 
between the last two operations, she's out there digging holes in the garden!  And 
puffing. We do snap at each other more than we used to. I probably don't know how 
she feels.’
Both patients and carers described the depression and mood changes associated 
with steroids. P2 ‘It was really difficult, especially when I was on high dose steroids - 
I was horrible, like a monster. He did say to me I was horrible. I think he used 
harsher words than that ‘.  C13 ‘At that time he was on very high doses of steroids 
and that just amplified all the emotions. He would fly off the handle at ridiculous 
things. I'd be thinking 'You've been half dead and you were alright with that, but the 
fact that the last Kitkat's been eaten?!’.  Patients and carers also reported the 
emotional impact of the illness. C8 ‘It would be nice to talk to somebody who cares 
for someone in the same position. That would be nice - to know that you're not on 
your own. I need to vent. Nobody understands. We've got lots of friends but nobody 
understands. I look normal but after 10 minutes work I'm exhausted. I've put in a 
bath lift upstairs. That does help me because I used to have to lift her in and out’. C5  
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‘He does get depressed sometimes but I get depressed sometimes too, I’ve got 
nobody to buck me up- do you know what I mean?’ 
Carers  described the impact of having to take time off work and trying to work 
around this. C1 ‘My boss was brilliant - come in when you can.  When it's over you 
can work extra hard’. C2 ‘My shifts changed at work so I could do the school run, go 
to work and come back to pick them up. I didn't do anywhere near 40 hours. So I did 
more childcare. C4 Now he's got that money [carers' allowance], I've got someone 
coming in to clean the oven’ C3 ‘Changing my work times round - my bosses were 
absolutely brilliant by the way. I've had to take a drop in money now and I'm no 
longer a manager, just a [lower position] so it takes the strain off of him if I'm at 
home.’ Yes and if I'd have had a worse boss, that would have directly cost me my job 
because I have to take so much time off.  
Need for constant vigilance
This theme describes the constant background monitoring that carers and patients 
articulated. P8 ‘I had a bad infection and ended up with sepsis. I don't now take 
anything for grnted. She is always looking out for me. She used to be the one to call 
the ambulance, now if I felt that way, I'd go to A&E’.
P7 ‘He does worry - I'd think twice before I said anything because he would act 
immediately. So he would possibly panic a little bit. On the whole, considering he 
was never a medical person, he's learned very well. I can't complain if someone's 
watching over me, can I? If there's something I'm not realising is happening to me, 
he would probably have noticed. He's really vigilant and doesn't particularly like 
leaving me alone so yes, it must have had an impact.’. In the context of a potentially 
serious illness, ‘keeping an eye on’ meant permanent vigilance for signs that the 
disease might be returning.
C1’When he was first diagnosed we did not go to bed. He sat in the chair, he was 
worried he’d got these nose bleeds. I honestly thought he was going to bed and 
would die. He slept on the settee down here and I put two chairs together and we did 
that every night. He wasn’t willing to go to bed because his mind was active, I wasn’t 
prepared to go to bed and leave him down there how he was feeling’. Others 
described how they checked on their partners breathing as a way of monitoring their 
condition. C10 ‘But the first thing I do every morning is listen for breathing. I don't 
know if she knows that - I might have told her. Sometimes she's very quiet - mostly 
you can hear [indicates laboured breathing], but sometimes I feel across to see if 
there's a warm hand. I feel guilty that I don't know what the illness is all about.’
C1 ‘Just, just keeping an eye on. One of the most frightening things before he got his 
diagnosis was his breathing at night. It wasn't just snoring - it sounded as though he 
was drowning. I was kicking him to wake him up and sometimes he wouldn't wake 
up. So when he started on his chemotherapy, it worked very quickly. I still wake up at 
night and check his breathing’. 
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Fear for the future 
This theme describes the fear that individuals experienced, particularly when they 
did not know what to expect. For those patients admitted to intensive care, their 
partners described emotional turmoil, especially dealing with the uncertainty of 
whether or not their partner would survive this life- threatening illness. C13 ‘And that 
afternoon he was blue-lighted up to hospital with me driving behind. Then another 
month in hospital, then DVT to add to it! I remember that first weekend in ITU, acute 
respiratory care, and sitting in the waiting room at 1am, so lonely, waiting to hear. 
And on the walls was all this bereavement advice! ‘. C15 ‘She was in hospital for 
about five weeks, three weeks of it in intensive care. I was told not to move too far 
from the telephone. It was quite an experience. There is that concern that we're both 
getting older. I am aware that the vasculitis will shorten her lifespan. The severity of 
the illness was often a shock. C2 ‘My worry is that I know one day we'll go to bed 
and I'll wake up and she won't. It could be tomorrow’. P1 ‘It’s always in the back of 
your mind. Until I got this shock. I never used to worry about nothing – absolutely 
nothing. If the house fell down I didn’t really care. But since I got this – corr’.
Both described triggers of emotional distress about what the future held and the 
inability to plan ahead .P1’Well we ain’t been on holiday for years. She’d like to go 
but I said I daren’t get on a plane, what with blood clots. And apart from that, if you’re 
on a plane and you’ve got all them germs going about. I used to love going on 
holiday. I say to her – next year we’ll go on holiday in this country. But at the time I 
just couldn’t be bothered. I felt so ill, stopped going on holiday’.
 Patients also worried the future and their life expectancy with many contemplating 
what might happen.  P5 ‘I do wonder what’s going to happen. Because the kidney 
could fail again and I’d have to go through all that again. And at my age they might 
not give me one so quick’.
P9 ‘I think I’m going to be fine but I do think about things now (death) I do. Where I’m 
going with this’.
P3 ‘I also worry about long-term health, life expectancy. Is this going to affect my life 
expectancy’. 
Discussion
In this study we have for the first time explored the role of carers in the lives of 
patients with a rare chronic rheumatic disease with a potentially severe outcome. To 
our knowledge this has never been studied before. The three emergent themes were 
the physical and psychological impact of the disease, the need for constant vigilance 
and fear of the future (Figure 1). All carers described the physical and emotional toll 
of caring, similar to that seen in carers of parents with osteoarthritis [23] in which 
three themes emerged: the physical and emotional work of caring, changes in family 
roles and the inequity of caring within the family. A study of family caregivers for 
patients with rheumatoid arthritis/ankylosing spondylitis, found the primary 
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consequences were loss of purchasing power, work problems, social isolation and 
emotional stress [24]. All the carers in our study experienced high stress levels 
relating to their partner’s diagnosis, a finding also seen in the cancer literature and of 
people with a rare genetic neurological disease (idiopathic basal ganglia 
calcification)[25-28] . 
Our study found that at diagnosis all patients described the psychological impact  
and physical impairments, a similar finding to others [8,19,29-31]. A study of 692 
vasculitis patients found they believed that their condition had affected their 
functional ability and emotional wellbeing [32].  A study of 410 AVV patients found 
74.8% reported high levels of fatigue associated with several factors, of which 
disturbed sleep and pain were the most important [33]. Participants in our study told 
of problems dealing with fatigue and sleepless nights. The diagnosis of a rare 
rheumatic condition impacts both the patient and carer, especially during the acute 
phase of the illness where patients can be critically ill. A literature review of the 
experiences of relatives of intensive care unit patients found they suffered anxiety, 
depression and fear [34]. 
After the acute phase of the illness,.  patients require regular and careful monitoring 
[35-36].  Our study found that ‘keeping an eye’ on the person made up the majority 
of the care provided, a similar finding to other studies of carers [37]. This constant 
monitoring is mirrored in the cancer literature as fear of recurrence is high in carers 
and cancer survivors [38]. Fear of disease progression is seen in patients with 
rheumatoid arthritis, diabetes and systemic sclerosis [39-40].
In our study, carers found this constant monitoring draining since they were 
concerned about the potentially serious consequences for the patient if they did not 
act appropriately. This was one of the main drivers for ‘fear of the future’- neither 
carer or patient knew clearly what would happen next, or what to look out for, feeling 
as if they were on a knife-edge between wellness i.e. stable, controlled disease 
requiring little if any immunosuppression, and serious illness with uncontrolled 
vasculitis. Relapse is unpredictable with at least half of patients with AAV 
experiencing a relapse at five years [41]. However, for patients and carers symptoms 
of a relapse are not easily recognised, making self-management difficult. Indeed, 
expert clinicians find it a challenge since no single test can predict relapse. A study 
comparing physician and patient global assessment scores of disease activity in 180 
GPA patients found disparity in the results [42], with patients able to detect a rise in 
disease activity three months before their physicians. Therefore it is important that 
patients’ perceptions of their disease activity are taken into account when assessing 
them [43]. There are several challenges for patients and carers in managing a rare 
condition: little or no previous experience and knowledge to draw upon, dealing with 
an unpredictable condition, the risk of relapse and the seriousness of treatment 
toxicity and side-effects. 
.Many recognised the side-effects of steroids, describing changes in personality, of 
anger and aggression attributed to high-dose steroids. This is a similar finding of 
AAV patients’ perceptions of the use of corticosteroids, who knew their positive 
benefits but were concerned about side-effects [9]. They also described a range of 
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emotional factors related to them, from anger, anxiety and depression and mood 
swings. 
A systematic review on the challenges of living with a rare condition found there 
were substantial psychological, physical, social and emotional impacts [44]. These 
opinions are consistent with this study. Fear of the future and dealing with 
uncertainty is common in the rare disease literature, [45-46].Patients with chronic 
conditions often become experts of their own condition but this is challenging in rare 
conditions. Patients with AAV reported difficulty adhering to complex medication 
regimes and understanding when to take their medication, and were slow to report 
symptoms and medication side-effects [47]. They believed that medication side-
effects would go away and did not want to trouble their doctor about these. This 
could be attributed to a lack of patient education, as we have shown previously that 
informational needs about medication are high in this group [48]. This could be that 
information was either not provided, or given at an inappropriate time, since patients 
have difficulty assimilating detailed information when acutely ill [8]. In our study some 
carers reminded patients when to take their medication and this is known to be 
associated with improved medication adherence [49]. We also found that as patients 
and carers became more experienced at living with AAV, they felt increasingly 
empowered to make decisions on the severity of the illness and act upon it.   
Strengths
The study has a number of strengths, we interviewed each pair of patients and 
carers separately on the same day. This helps maintain independence of the 
interviews and so obtain the distinct views of carers and patients. 
Weaknesses 
This study has several potential weaknesses. We could not validate the type of care 
and time spent in caring, there may be recall bias for the interviews and both patient 
and carer may have under or overestimated the level of support needed / provided. 
However, this was minimised by interviewing both patient and carer on the same 
day. 
Conclusion 
This is the first study of the role informal carers provide to patients with with AAV, a 
rare chronic rheumatic disease, and it makes a significant contribution to our 
knowledge. The study suggests that the role of carers is under-recognised, in 
particular the emotional toll. All the carers in our study experienced high stress levels 
relating to their partner’s diagnosis. and he need for constant vigilance was draining. 
. Health care professionals should address individual’s fears and expectations and  
ask carers how they are coping and if they require any support. 
Figure legend
Figure 1 Emergent Themes
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Table 1 Patient characteristics
GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; EGPA: 
eosinophilic granulomatosis with polyangiitis.
Participant Gender Age Disease 
Duration
      
Disease 
P1 M 68 6   years GPA
P2 F 34 2   years EGPA
P3 M 55 2   years GPA
P4 M 76 7   years MPA
P5 M 74 7   years MPA
P6 M 71 7   years EGPA
P7 M 76 3   years EGPA
P8 F 68 16 years EGPA
P9 F 72 1   year MPA
P10 F 74 20 years GPA
P11 M 66 3   years GPA
P12 M 70 7   years GPA
P13 F 55 2   years GPA
P14 M 76 14 years GPA
P15 M 60 14 years GPA
P16 F 76 15 years GPA
P17 M 68 7   years GPA
P18 F 67 5   years MPA
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Table 2 Carers characteristics  
Participant Gender Age Employment status Relationship 
C1 F 66 Retired Partner 
C2 M 38 Full time Partner 
C3 F 42 Full time Partner 
C4 F 78 Retired Partner
C5 F 70 Retired Partner
C6 F 71 Retired Partner
C7 M 76 Retired Partner
C8 M 70 Retired Partner
C9 M 75 Retired Partner
C10 M 70 Retired Partner
C11 M 66 Retired Partner
C12 F 66 Retired Partner
C13 M 65 Part-time Partner
C14 F 45 Full time Partner
C15 M 60 Retired Partner
C16 F 76 Retired Partner
C17 M 68 Retired Partner
C18 F 67 Retired Partner
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 Figure 1 Emergent Themes 
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